Metformin is used in horses with diagnosed EMS and/or in horses with chronic or recurrent laminitis. It inhibits gluconeogenesis, decreases hepatic glucose production, and increases glucose transporter type 4 on the cell membranes of skeletal muscle cells. But, the oral bioavailability of Metformin in horses is poor (3.9-7.1%).
 
Metformin changes the gut microbiome composition in humans by increasing levels of Akkermansia spp. which significantly improves glucose tolerance and decreases adipose tissue.
 
We haven't noticed a similar increase in horses with EMS (from our population database of thousands of horses) but we have seen an increase in Akkermansia in horses by using a natural plant compound called ecdysterone, Chenopodium Album.
 
An increase in Akkermansia muciniphila and other beneficial bacteria of the gut boosts the production of short-chain fatty acids which are positively correlated to the anti-inflammatory interleukin-10 and decreased systemic inflammation in horses.
 
Von Münchow, A., Torp Yttergren, S., Jakobsen, R. R., Luthersson, N., Hansen, A. K., & Lindenberg, F. (2023). Oligosaccharide feed supplementation reduces plasma insulin in geldings with Equine Metabolic Syndrome. Frontiers in Microbiomes, 2, 1194705.
 
Pack Size 100g